Multidrug-resistant tuberculosis.
作者信息
D'Ambrosio Lia, Centis Rosella, Migliori Giovanni B
出版信息
N Engl J Med. 2012 Nov 29;367(22):2154; author reply 2155-6. doi: 10.1056/NEJMc1210001.
Abstract
摘要
相似文献
1
Multidrug-resistant tuberculosis.
N Engl J Med. 2012 Nov 29;367(22):2154; author reply 2155-6. doi: 10.1056/NEJMc1210001.
2
Multidrug-resistant tuberculosis.
N Engl J Med. 2012 Nov 29;367(22):2155; author reply 2155-6. doi: 10.1056/NEJMc1210001.
3
Multidrug-resistant tuberculosis.
N Engl J Med. 2012 Nov 29;367(22):2154-5; author reply 2155-6. doi: 10.1056/NEJMc1210001.
4
Confronting multidrug-resistant tuberculosis.
N Engl J Med. 2012 Jun 7;366(23):2223-4. doi: 10.1056/NEJMe1204478.
5
Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis.
Prescrire Int. 2017 Apr;26(181):89-92.
6
Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.
Eur Respir J. 2018 Jun 14;51(6). doi: 10.1183/13993003.00159-2018. Print 2018 Jun.
7
Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Lancet Respir Med. 2017 Oct;5(10):772-774. doi: 10.1016/S2213-2600(17)30309-0. Epub 2017 Sep 5.
8
[New antitubercular agents are not where where we need them to be].
Rev Med Suisse. 2015 Dec 16;11(499):2408-9.
9
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
Eur Respir J. 2018 Jul 4;52(1). doi: 10.1183/13993003.00934-2018. Print 2018 Jul.
10
India plans to expand access to new tuberculosis drug.
Lancet. 2017 Feb 18;389(10070):685. doi: 10.1016/S0140-6736(17)30394-X. Epub 2017 Feb 17.
引用本文的文献
1
Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs.
Pharmacoeconomics. 2014 Jul;32(7):617-26. doi: 10.1007/s40273-014-0159-5.
2
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27.
本文引用的文献
1
Confronting multidrug-resistant tuberculosis.
N Engl J Med. 2012 Jun 7;366(23):2223-4. doi: 10.1056/NEJMe1204478.
2
Delamanid for multidrug-resistant pulmonary tuberculosis.
N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433.
3
Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones.
Eur Respir J. 2012 Oct;40(4):814-22. doi: 10.1183/09031936.00036812. Epub 2012 May 31.
4
Scaling up interventions to achieve global tuberculosis control: progress and new developments.
Lancet. 2012 May 19;379(9829):1902-13. doi: 10.1016/S0140-6736(12)60727-2.
5
Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis.
Eur Respir J. 2012 Jun;39(6):1511-9. doi: 10.1183/09031936.00125711. Epub 2011 Oct 17.
Zotero 插件